GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enveric Biosciences Inc (STU:SLZ) » Definitions » Total Liabilities

Enveric Biosciences (STU:SLZ) Total Liabilities : €1.42 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Enveric Biosciences Total Liabilities?

Enveric Biosciences's Total Liabilities for the quarter that ended in Dec. 2024 was €1.42 Mil.

Enveric Biosciences's quarterly Total Liabilities increased from Jun. 2024 (€0.60 Mil) to Sep. 2024 (€0.76 Mil) and increased from Sep. 2024 (€0.76 Mil) to Dec. 2024 (€1.42 Mil).

Enveric Biosciences's annual Total Liabilities declined from Dec. 2022 (€3.77 Mil) to Dec. 2023 (€2.15 Mil) and declined from Dec. 2023 (€2.15 Mil) to Dec. 2024 (€1.42 Mil).


Enveric Biosciences Total Liabilities Historical Data

The historical data trend for Enveric Biosciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enveric Biosciences Total Liabilities Chart

Enveric Biosciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.56 3.91 3.77 2.15 1.42

Enveric Biosciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.15 2.18 0.60 0.76 1.42

Enveric Biosciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Enveric Biosciences's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=2.944-1.521
=1.42

Enveric Biosciences's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities=Total Assets (Q: Dec. 2024 )-Total Equity (Q: Dec. 2024 )
=2.944-1.521
=1.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enveric Biosciences Total Liabilities Related Terms

Thank you for viewing the detailed overview of Enveric Biosciences's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Enveric Biosciences Business Description

Traded in Other Exchanges
Address
4851 Tamiami Trail N, Suite 200, Naples, FL, USA, 34103
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.